Drug
Sepofarsen clinical trials
Also written QR-110.
Keep track of what changes. Save the sepofarsen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Laboratoires Thea (3) · ProQR Therapeutics (2)
Studies
Open first, then newest update. How each study uses sepofarsen is read from its arms, and is right about nine times in ten.
Testing it · 5
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)RecruitingPhase 3Laboratoires TheaNCT06891443Written as sepofarsen
- Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneCompletedPhase 1/2Laboratoires TheaNCT03140969Written as QR-110
- Extension Study to Study PQ-110-001 (NCT03140969)TerminatedPhase 1/2Laboratoires TheaNCT03913130Written as QR-110
- An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.Status unknownPhase 2/3ProQR TherapeuticsNCT04855045Written as sepofarsen
- A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)Active, not recruitingPhase 2/3ProQR TherapeuticsNCT03913143Written as sepofarsen
Codes
What other systems call sepofarsen · ClinicalTrials.gg INT015453
- UNII (FDA) 7CAZ46X8ELSEPOFARSENOne source FDA
- NCI Thesaurus C171740SepofarsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7CAZ46X8EL | SEPOFARSEN | One source FDA |
| NCI Thesaurus | C171740 | Sepofarsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.